Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints

Semin Immunol. 2019 Jun:43:101299. doi: 10.1016/j.smim.2019.101299.

Abstract

The interferons (IFNs) are cytokines with important antineoplastic and immune modulatory effects. These cytokines have been conserved through evolution as important elements of the immune surveillance against cancer. Despite this, defining their precise and specific roles in the generation of antitumor responses remains challenging. Emerging evidence suggests the existence of previously unknown roles for IFNs in the control of the immune response against cancer that may redefine our understanding on how these cytokines function. Beyond the engagement of classical JAK-STAT signaling pathways that promote transcription and expression of gene products, the IFNs engage multiple other signaling cascades to generate products that mediate biological responses and outcomes. There is recent emerging evidence indicating that IFNs control the expression of both traditional immune checkpoints like the PD-L1/PD1 axis, but also less well understood "intracellular" immune checkpoints whose targeting may define new approaches for the treatment of malignancies.

Keywords: Cancer; Immune checkpoint; Immune response; Interferon; Non-canonical pathways; Signaling.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • B7-H1 Antigen / metabolism
  • Humans
  • Immunity
  • Immunologic Surveillance
  • Immunotherapy / trends*
  • Interferons / metabolism*
  • Neoplasms / immunology*
  • Programmed Cell Death 1 Receptor / metabolism
  • Signal Transduction

Substances

  • B7-H1 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Interferons